Ken Griffin Stoke Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $201,468 - $692,913	48,900 Added 5433.33%	49,800 $672,000
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $1,011 - $1,620	-300 Reduced 25.0%	900 $4,000
Q3 2023 Nov 14, 2023	SELL	$3.78 - $11.99 $34,776 - $110,308	-9,200 Reduced 88.46%	1,200 $4,000
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $11,102 - $19,348	-1,400 Reduced 11.86%	10,400 $110,000
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $26,010 - $35,292	-3,400 Reduced 22.37%	11,800 $98,000

Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $107,464 - $238,488	15,200 New	15,200 $140,000

111

50M

63K

111K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $499M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.